enzastaurin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms, Cancer
Trial Timeline
Mar 1, 2006 → Jul 1, 2009
NCT ID
NCT00309140About enzastaurin
enzastaurin is a phase 2 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00309140. Target conditions include Neoplasms, Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432951 | Phase 1 | Completed |
| NCT00744991 | Phase 2 | Completed |
| NCT00718419 | Phase 2 | Completed |
| NCT00542919 | Phase 2 | Completed |
| NCT00475644 | Phase 2 | Completed |
| NCT00452257 | Phase 1 | Completed |
| NCT00420381 | Phase 2 | Completed |
| NCT00428714 | Phase 2 | Completed |
| NCT00309140 | Phase 2 | Completed |
| NCT00088205 | Phase 2 | Completed |
| NCT00190723 | Phase 2 | Completed |
Competing Products
20 competing products in Neoplasms